Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

Fig. 2

a. The figure shows the significantly higher expression of VEGF-121 in the plasma of patients with recurrent GB (Pre-BEV) in comparison to the healthy patients (HC) (p = 0.0002, Mann-Whitney t test). After bevacizumab treatment (Post-BEV) patients with recurrent GB showed a significant reduction of the human VEGF-121 plasma level (p = 0.0002, Mann-Whitney t test); b. The figure shows the significant correlation between plasma level of VEGF-121 and cancer tissue VEGF-121 mRNA expression (linear regression, r2 = 0.9447, p = 0.0001); c. The figure shows the significant correlation between plasma level of VEGF-121 and contrast enhancing tumor area (linear regression, r2 = 0.8248, p = 0.0003)

Back to article page